RxDoctor Payments Data

Ariel Bina, PA

Physician Assistant · Tarzana, CANPI 1265187017

Payments from drug & device makers

$16,282in general payments, 2019–2025

Across 644 payments — averaging $25.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$2K
  • Bard Peripheral Vascular, Inc.$1K
  • Shockwave Medical, Inc$1K
  • Abbott$831
  • Tactile Systems Technology Inc$821
  • Merck$778
  • plus $9K from 40 others

What the payments were for

  • Food & beverage$16,268100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,282 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$14,222
Medicare patients
111
Services billed
173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide278$369,143
VyndamaxTafamidis11$269,167
EliquisApixaban314$261,112
Repatha SureclickEvolocumab211$169,951
TrulicityDulaglutide125$156,738
XareltoRivaroxaban160$145,582
EntrestoSacubitril/Valsartan136$142,577
OzempicSemaglutide66$78,207
JardianceEmpagliflozin85$65,708
SynjardyEmpagliflozin/Metformin Hcl55$45,805
RybelsusSemaglutide27$36,083
VascepaIcosapent Ethyl75$30,107
Metformin Er GastricMetformin Hcl16$28,155
LinzessLinaclotide27$20,407
VerquvoVericiguat26$19,494

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$202$530,279325 claims
Lilly USA, LLCMounjaro, Trulicity$622$525,881403 claims
Johnson & JohnsonXarelto$110$145,582160 claims
NovartisEntresto$746$142,577136 claims
Boehringer IngelheimJardiance, Synjardy, Synjardy Xr, Tradjenta$688$132,352164 claims
Novo NordiskOzempic, Rybelsus$259$114,29193 claims
MerckVerquvo, Januvia$778$30,06943 claims
AstraZenecaBrilinta$562$18,60534 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Tarzana

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →